We have been representing patients and their family in drug injury lawsuits for the past 16 years and this is our main practice area.
Drug injury legal compensation cases involve personal injury or wrongful death claims filed on behalf of people who, unfortunately, experienced a serious side effect, had an adverse drug reaction, or died from their use of a prescription medication.
Given our many years of experience handling these types of lawsuits we know drug injury cases deserve special attention.
Drug injury claims have a personal aspect which must be appreciated and respected by the attorney handling your case. At our law firm, we do not underestimate nor lose sight of the trust which is being placed in us by clients when they select us to represent them for their lawsuit against the responsible pharmaceutical company.
We will handle your drug injury case not only competently and professionally, but with genuine care and understanding. Any inquiries from our clients are responded to promptly, and telephone calls are always returned without delay.
If you, relatives, or friends need legal advice or legal representation for a personal injury lawsuit or a wrongful death lawsuit involving a drug side effect, the Law Offices of Thomas J. Lamb is here to help.
We encourage you to submit a Drug Injury Law Case Review — it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, or some other lawyer — about your case based on his many years of experience.
We handle these drug injury cases on a contingency fee basis, meaning that there is no payment for our legal services until we are successful in getting legal compensation for you.
While our office is in Wilmington, North Carolina, we have successfully handled drug injury lawsuits for people all over the United States.
It is important to note that we do not put our clients into large class actions. Rather we favor an individual lawsuit approach, which allows us to give personal attention to each of our clients, from start to finish.
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Legal & Medical News: Featured Article
In July 2016 Boehringer Ingelheim Pharmaceuticals, Inc. received a Supplemental Approval letter from the FDA concerning a label change about fatal cases of ketoacidosis which have been reported concerning Jardiance, Synjardy, and Glyxambi. These relatively new diabetes medicines are part of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors class of drugs.
In June 2016 the FDA announced it has strengthened the existing warning about the risk of acute kidney injury for Invokana and Invokamet as well as Farxiga and Xigduo XR.
As regards a different type of side effect, we point out this May 2016 document, “FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate”.
Since then, we have not heard again from the FDA about the results of this investigation regarding leg, foot, and toe amputations possibly caused by the use of Invokana and Invokamet. But recently the European Medicines Agency (EMA)’s Pharmacovigilance Risk Assessment Committee (PRAC) announced that their investigation about such amputations now includes all the diabetes medicines in the SGLT2 Inhibitors class of drugs, such as Farxiga and Jardiance.
Also in May 2016 a Black-Box Warning about lactic acidosis added to the label for Invokamet, as seen on this FDA Safety Information page, “Invokamet (canagliflozin and metformin HCl) Tablets”.
The May 2016 revised Invokana label know includes this drug side effect warning information:
Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain….
We will continue to monitor the safety profile for this SGLT2 Inhibitors class of drugs, watching for future label changes with increased side effects warnings, the results of safety investigations by the FDA and the EMA, etc.
- Viagra / Cialis / Levitra – Melanoma: July 2016 Medical / Legal Update
- Doctors Are Concerned About Lack Of Savaysa Antidote To Stop Bleeding
- FDA: Acute Kidney Injury Due To Invokana, Invokamet, Farxiga, Xigduo
- Zecuity Recall Follows June 2016 FDA Warning About Burns And Scarring
- How Long-Term Use Of Heartburn Drug Nexium Might Cause Kidney Problems
- Lyrica Use During Pregnancy Increases The Risk Of Major Birth Defects
- Fosamax – Femur Fracture Litigation: 4400 Cases; No Trials; Appeals
- February 2016 Tecfidera Label Change Adds Information About PML Risks